Search Results
You are looking at 1 - 2 of 2 items for
- Author: A Al Ghuzlan x
- Refine by access: All content x
Search for other papers by D Deandreis in
Google Scholar
PubMed
Search for other papers by A Al Ghuzlan in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by L Lacroix in
Google Scholar
PubMed
Search for other papers by J P Garsi in
Google Scholar
PubMed
Search for other papers by M Talbot in
Google Scholar
PubMed
Search for other papers by J Lumbroso in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by B Caillou in
Google Scholar
PubMed
Search for other papers by J M Bidart in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
The aim of this study is to search for relationships between histology, radioiodine (131I) uptake, fluorodeoxyglucose (FDG) uptake, and disease outcome in patients with metastatic thyroid cancer. Eighty patients with metastatic thyroid cancer (34 males, 46 females, mean age at the time of the diagnosis of metastases: 55 years) were retrospectively studied. All patients were treated with radioactive iodine and evaluated by FDG-positron emission tomography (PET). Primary tumor tissue sample was available in all cases. Forty-five patients (56%) had a papillary, 12 (15%) a follicular, and 23 (29%) a poorly differentiated thyroid cancer. Cellular atypias, necrosis, mitoses, thyroid capsule infiltration, and vascular invasion were frequently detected (70, 44, 52, 60, and 71% respectively). Metastases disclosed FDG uptake in 58 patients (72%) and 131I uptake in 37 patients (45%). FDG uptake was the only significant prognostic factor for survival (P=0.02). The maximum standardized uptake value and the number of FDG avid lesions were also related to prognosis (P=0.03 and 0.009). Age at the time of the diagnosis of metastases (P=0.001) and the presence of necrosis (P=0.002) were independent predictive factors of FDG uptake. Radioiodine uptake was prognostic for stable disease (P=0.001) and necrosis for progressive disease at 1 year (P=0.001). Histological subtype was not correlated with in vivo tumor metabolism and prognosis. In conclusion, FDG uptake in metastatic thyroid cancer is highly prognostic for survival. Histological subtype alone does not correlate with 131I/FDG uptake pattern and patient outcome. Well-differentiated thyroid cancer presenting histological features such as necrosis and FDG uptake on PET scan should be considered aggressive differentiated cancers.
Search for other papers by C Nascimento in
Google Scholar
PubMed
Search for other papers by I Borget in
Google Scholar
PubMed
Search for other papers by A Al Ghuzlan in
Google Scholar
PubMed
Search for other papers by D Deandreis in
Google Scholar
PubMed
Search for other papers by L Chami in
Google Scholar
PubMed
Search for other papers by J P Travagli in
Google Scholar
PubMed
Search for other papers by D Hartl in
Google Scholar
PubMed
Search for other papers by J Lumbroso in
Google Scholar
PubMed
Search for other papers by C Chougnet in
Google Scholar
PubMed
Search for other papers by L Lacroix in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
131I is given in differentiated thyroid cancer (DTC) without taking into account thyroglobulin (Tg) levels at the time of ablation, whereas 6–18 months later it is a major criterion for cure. This single-center retrospective study assessed the frequency and risk factors for persistent disease on postablation whole body scan (WBS) and postoperative neck ultrasonography (n-US) and for recurrent disease during the subsequent follow-up, in patients with DTC and undetectable TSH-stimulated Tg level (TSH–Tg) in the absence of Tg antibodies (TgAb) at the time of ablation. Among 1031 patients ablated, 242 (23%) consecutive patients were included. Persistent disease occurred in eight cases (3%) (seven abnormal WBS and one abnormal n-US), all with initial neck lymph node metastases (N1). N1 was a major risk factor for persistent disease. Among 203 patients with normal WBS and a follow-up over 6 months, TSH–Tg 6–18 months after ablation was undetectable in the absence of TgAb in 173 patients, undetectable with TgAb in 1 patient and equal to 1.2 ng/ml in 1 patient. n-US was normal in 152 patients and falsely positive in 3 patients. After a mean follow-up of 4 years, recurrence occurred in two cases (1%), both with aggressive histological variants. The only risk factor for recurrence was an aggressive histological variant (P=0.03). In conclusion, undetectable postoperative TSH–Tg in the absence of TgAb at the time of ablation is frequent. In these patients, repeating TSH–Tg 6–18 months after ablation is not useful. 131I ablation could be avoided in the absence of N1 and aggressive histological variant.